Abstract
Guillain-Barre syndrome is a frequently post-infectious, autoimmune acute inflammatory polyradiculoneuropathy affecting all age groups. It typically results in rapid-onset weakness symmetrically affecting proximal and distal muscles. Cranial muscles are not infrequently affected and respiratory muscle weakness requiring mechanical ventilation occurs in 25% of cases. The incidence is around 1-2 per 100,000/year. Various clinical, electrophysiological and immunological subtypes are described. Plasma exchanges (PE) and intravenous immunoglobulins (IVIg) represent the main treatment options. PE were shown to be effective on rate of recovery in randomized trials. Subsequently further trials have demonstrated the equivalence of IVIg. IVIg are frequently the preferred option for practical reasons. Treatment can result in reversible clinical fluctuations which need to be readily recognized. Although number of PE appears to be optimally of 4, except in mildly affected patients where only 2 may suffice, the dosage of IVIg conventionally administered (2 g/kg) may be sub-optimal in some patients. This may relate to a relationship between IVIg pharmacokinetics and clinical outcome. Studies are under way to evaluate the usefulness of a second IVIg course in severely-affected GBS patients. There is no evidence for use of corticosteroids in GBS. Both IVIg and PE are costly and despite their use and established effectiveness, there is still a need for new treatments to lessen disability. Further research is warranted in optimizing currently available therapies as well as finding others to effectively improve the management of this potentially devastating condition.
Keywords: Guillain-Barre syndrome, intravenous immunoglobulins, plasma exchange, treatment, polyradiculoneuropathy, Campylobacter jejuni enteritis, cerebrospinal fluid, Acute Motor Axonal Neuropathy, Acute Motor and Sensory Axonal Neuropathy, Acute Inflammatory Demyelinating Polyradiculoneuro-pathy
Inflammation & Allergy - Drug Targets (Discontinued)
Title:Treatment of Guillain-Barre Syndrome: A Review
Volume: 11 Issue: 4
Author(s): Yusuf A. Rajabally
Affiliation:
Keywords: Guillain-Barre syndrome, intravenous immunoglobulins, plasma exchange, treatment, polyradiculoneuropathy, Campylobacter jejuni enteritis, cerebrospinal fluid, Acute Motor Axonal Neuropathy, Acute Motor and Sensory Axonal Neuropathy, Acute Inflammatory Demyelinating Polyradiculoneuro-pathy
Abstract: Guillain-Barre syndrome is a frequently post-infectious, autoimmune acute inflammatory polyradiculoneuropathy affecting all age groups. It typically results in rapid-onset weakness symmetrically affecting proximal and distal muscles. Cranial muscles are not infrequently affected and respiratory muscle weakness requiring mechanical ventilation occurs in 25% of cases. The incidence is around 1-2 per 100,000/year. Various clinical, electrophysiological and immunological subtypes are described. Plasma exchanges (PE) and intravenous immunoglobulins (IVIg) represent the main treatment options. PE were shown to be effective on rate of recovery in randomized trials. Subsequently further trials have demonstrated the equivalence of IVIg. IVIg are frequently the preferred option for practical reasons. Treatment can result in reversible clinical fluctuations which need to be readily recognized. Although number of PE appears to be optimally of 4, except in mildly affected patients where only 2 may suffice, the dosage of IVIg conventionally administered (2 g/kg) may be sub-optimal in some patients. This may relate to a relationship between IVIg pharmacokinetics and clinical outcome. Studies are under way to evaluate the usefulness of a second IVIg course in severely-affected GBS patients. There is no evidence for use of corticosteroids in GBS. Both IVIg and PE are costly and despite their use and established effectiveness, there is still a need for new treatments to lessen disability. Further research is warranted in optimizing currently available therapies as well as finding others to effectively improve the management of this potentially devastating condition.
Export Options
About this article
Cite this article as:
A. Rajabally Yusuf, Treatment of Guillain-Barre Syndrome: A Review, Inflammation & Allergy - Drug Targets (Discontinued) 2012; 11 (4) . https://dx.doi.org/10.2174/187152812800959059
DOI https://dx.doi.org/10.2174/187152812800959059 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Comparison and Impact of The Short-Term Use of Some Non-Aspirin NSAIDs on Bleeding Time of Mice
Cardiovascular & Hematological Agents in Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Therapeutic Medical Hypothermia-A Multispecialty Approach
Recent Patents on Cardiovascular Drug Discovery A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway
Current Signal Transduction Therapy The Vpu Protein and its Role in HIV-1 Pathogenesis
Current Genomics HER-2 / neu and Topoisomerase IIα - Simultaneous Drug Targets in Cancer
Combinatorial Chemistry & High Throughput Screening The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene Expression Analysis for High Throughput Screening Applications
Combinatorial Chemistry & High Throughput Screening Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Osteoblast Differentiation and Control by Vitamin D and Vitamin D Metabolites
Current Pharmaceutical Design Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance
Current Vascular Pharmacology Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Editorial [Hot Topic Advantages and Disadvantages of Inhaled Corticosteroids in the Treatment of Pulmonary Diseases Guest Editor: Nazan Cobanoglu]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry G-Protein-Coupled Receptors Oligomerization: Emerging Signaling Units and New Opportunities for Drug Design
Current Protein & Peptide Science Calixarenes in Bio-Medical Researches
Current Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Editorial Hot Topic: Molecular Biology-Pathophysiology of Inflammation and Autoinflammation (Guest Editor: Kostas Konstantopoulos)]
Current Drug Targets - Inflammation & Allergy Strategies to Reduce Oxidative Stress in Glaucoma Patients
Current Neuropharmacology